Orchid Pharma Limited has informed the Exchange about Shareholders meeting

Nclt Scheme FiledStrategic Transactions View source PDF Explain this filing

ORCHPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.5%Reaction day

₹702.50

prior close

₹706.45

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.5%-0.0% vs market

Pharmaceuticals peers, median of 150sector+0.6%-0.1% vs sector

On the reaction day the stock moved in line with Nifty Microcap 250 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

+0.1

15m

+0.4

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.5+0.5-0.0+0.6-0.1

Next day

+1.7+1.4+0.3+1.4+0.3

+5.3+1.5+3.8+1.4+3.9

+3.0+1.3+1.7+1.0+2.0

+6.6+1.3+5.2+1.0+5.5

+7.2+1.8+5.4+1.6+5.5

+3.3+1.2+2.2+0.6+2.8

15d

+4.2+3.1+1.1+3.8+0.4

-0.3-0.8+0.5+1.3-1.7

+6.2-3.5+9.7-3.7+9.9

+1.1-3.7+4.8-3.6+4.6

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Orchid Pharma held an NCLT-convened meeting of its equity shareholders on June 26, 2025, to consider and approve the Scheme of Amalgamation and Arrangement with Dhanuka Laboratories Limited (the Amalgamating Company). The meeting was initially adjourned for 30 minutes due to lack of quorum, then resumed via video conferencing with Mr. R. Varadharajan (NCLT-appointed Chairperson) presiding. Remote e-voting ran from June 23 to June 25, 2025, with an additional 30-minute voting window after the meeting concluded. The Managing Director briefed shareholders on the merger scheme. Voting results by the Scrutinizer (Ms. Vinitha Varshini K) are awaited and will be shared with NSE, BSE, and posted on the company's and NSDL websites within prescribed timelines.

Likely market impact

This is a procedural step in the NCLT approval process for the Dhanuka–Orchid Pharma merger. Shareholders should watch for the e-voting results, which will indicate whether the amalgamation has secured the required shareholder approval to proceed to the next stage.